Articles from Basilea Pharmaceutica International Ltd, Allschwil

Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

Allschwil, Switzerland, October 20, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · October 20, 2026

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

Allschwil, Switzerland, September 14, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · September 14, 2026

Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · August 18, 2026

Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · August 5, 2026

Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · July 29, 2026

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · May 28, 2026

Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting

Allschwil, Switzerland, April 15, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · April 15, 2026

Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · April 9, 2026

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

Allschwil, Switzerland, March 23, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · March 23, 2026

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 25, 2026

Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 17, 2026

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, February 09, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 9, 2026